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A prediction was made here in January 2009, that
the market for company mergers and acquisiti-
ons in the pharmaceutical industry would con-
tinue to reach a high level in 2009, even after the
announced cases of large M&As (e.g. Novar-
tis/Alcon, Roche/Genentech, Teva/Barr Pharma)
in 2008. This forecast was attempted even though
it was clear that the so-called 6th M&A wave was
drawing to a close after encountering increasing
problems in raising outside capital, especially
after the collapse of Lehman Brothers in Septem-
ber 2008. And indeed, when considered as a whole,
the M&A year 2009 – and the first months of 2010
are not showing any considerable improvement
– was a weak M&A year: the global M&A trans-
action volume fell from approx. US$ 4.200 bn in
2007 (2006: approx. US$ 3.400 bn) to a mere US$
2.500 bn in 2008, to then only accumulate a volu-
me of approx US$ 1.300 bn in 2009. This decline
is even more distinctive at a European level and
thus shows that US and Asian companies are
increasingly setting the tone for M&A transac-
tions. Furthermore, the global share of financial
investors in purchase volume took a plunge from
26% in 2006 to 8% in 2009. Companies - so-cal-
led strategic investors - must therefore stem the
remaining low M&A volume on their own.
Pharmaceutical M&A remain at a high
level in 2009
In retrospect, the prognosis for a strong M&A year
2009 for pharmaceuticals was quite accurate: In
January 2009, Pfizer announced they would be
taking over their competitor Wyeth for US$ 68
bn. Shortly after, Merck & Co. followed suit with
their report on the acquisition of Schering-Plough
for US$ 41 bn. Other examples of further large-
scale M&A cases in the pharmaceutical sector
were the takeover of the Czech generics manu-
facturer Zentiva by Sanofi-Aventis (approx. US$
2 bn), the acquisition of the US skin-care specia-
list Stiefel Laboratories by GlaxoSmithKline
(approx. US$ 2.9 bn), the complete takeover of the
joint venture Merial (animal health) by Sanofi-
Aventis from Merck & Co. (approx. US$ 4 bn) and
the takeover of the pharmaceutical sector of Sol-
vay by the Belgian company Abbott Laboratories
(approx. € 4.5 bn).
In March 2010, both the announced US$ 5.3 bn
takeover of Millipore by the German Darmstadt-
based company Merck and the takeover of Ratio-
pharm by Teva (approx. € 3.6 bn) show that the
M&A market wheels are still running smoothly
in the pharmaceutical industry. The M&A com-
munity is increasingly seeing cases such as
Merck/Millipore as an indicator or guiding light
for a general re-ignition of the M&A market. What
is causing this exceptional situation in the phar-
maceutical M&A market and what are the pro-
bable developments for 2010 and 2011? Why does
the generics business appear to raise interest
again even though major pharmaceutical com-
panies had a tendency to part with it in the last
decade?
Global weak economic phase promotes
consolidation
Generally, it can be said that the worldwide finan-
cial crisis is not only influencing the amount of
drugs being sold but is also increasingly pressu-
rizing the pharmaceutical industry’s pricing. The
demographic development of economically advan-
ced nations is leading to a steady increase of health
costs - with simultaneous national budget defi-
cits. Pressure is therefore mounting to minimize
the costs of the health system by means of regu-
latory measures. In addition, the drug pipelines
are quite low and many blockbuster drugs with
bn. US$ turnovers will soon be disappearing as a
source of revenue for the pharmaceutical giants.
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Generic drug manufacturers such as Teva, Mylan
or STADA are growing and are also in the middle
of a consolidation process (e.g. Merck Generics
being acquired by Mylan in 2007, takeover of
Ratiopharm by Teva). Pressure is building up
immensely for the group of research-based phar-
maceutical companies who were pampered by
success so far. They rapidly have to increase their
efficiency by tapping into synergies in e.g. R&D,
procurement or administration.
Generic drug manufacturers are beco-
ming more attractive
When on their shopping spree, research-based
pharmaceutical companies no longer shy away
from taking over generic drug manufacturers and
thus acquiring a „turnover base line“ – even if the
margin is not enormous – which they use as a
value argument when presenting to their share-
holders. One example is the huge interest Pfizer
showed in taking over Ratiopharm: the patent
protection for several Pfizer drugs will be expi-
ring in the coming years and Ratiopharm would
have been a good opportunity to generate fur-
ther efficient growth. Shortly after the takeover
of Wyeth, Pfizer followed high increase in effi-
ciency objectives by closing down sites, for exam-
ple. It remains to be seen if high takeover prices
can be justified, such as the US$ 41 bn paid by
Merck & Co. for Schering-Plough and the thus
acquired drug pipeline. It is currently hard to pre-
dict the transaction value of the approx. 20 phase
III drugs that Merck & Co. acquired with the deal.
Biotech as a major driver of pharma-
ceutical consolidation
Apart from the drivers „Synergy by economies of
scale“ and „Purchase of drug pipelines“, there are
increasing signs that pharmaceutical companies
are placing their bets on producing biological
blockbusters alongside small molecules. Next to
the general risk reduction coming along with a
product portfolio diversification biotech invest-
ments contain a “copy protection” which results
from high financial and know-how requirements
to copy biotech products. Biotech as a driver for
M&A or the intensification of cooperations was
probably the motivation driver for the following
M&A deals: MedImmune/AstraZeneca (in 2007
for approx. US$ 15 bn), Merck/Serono (in 2006 for
about € 10.1 bn), Merck/Millipore (in 2010 for
approx. € 5.4 bn) or Astellas Pharma/OSI Pharma-
ceuticals (offering US$ 3.5 bn in 2010). Takeovers
of especially small biotech companies are sim-
plified by the high financial need for product
development or market entry. Since these requi-
red loans are not available through banks or finan-
cial investors, it offers a perfect investment oppor-
tunity for large financially sound pharmaceuti-
cal players.
Justifying high acquisition prices by
efficiency improvement in difficult mar-
kets
In conclusion, not only increasing efficiency pres-
sure but also dried-out pipelines will increase the
consolidation pressure on the pharmaceutical
sector in the near future. In addition, biotech will
„mature“ and by doing so, will become an inte-
gral part of larger pharmaceutical companies. It
will become important for the success of phar-
maceutical M&A cases to justify the often high
acquisition prices with future turnover in parti-
ally difficult markets or through cost savings. This
is where it calls for the merging partners to imple-
ment a high quality post merger integration and
in doing so to sufficiently take into considerati-
on the particularities of national clients and also
the cultural differences of the own workforce.
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